High Tower Advisors, LLC Arrowhead Pharmaceuticals, Inc. Transaction History

High Tower Advisors, LLC

$68.3 Billion
Q3 2024

A detailed history of High Tower Advisors, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 123,477 shares of ARWR stock, worth $2.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

123,477

Previous 110,771 11.47%

Holding current value

$2.41 Million

Previous $2.88 Million 16.96%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.36 - $29.54 $245,988 - $375,335	12,706 Added 11.47%	123,477 $2.39 Million
Q2 2024 Aug 13, 2024	BUY	$21.87 - $28.24 $215,375 - $278,107	9,848 Added 9.76%	110,771 $2.88 Million
Q1 2024 May 06, 2024	BUY	$27.21 - $39.48 $417,401 - $605,623	15,340 Added 17.92%	100,923 $2.89 Million
Q4 2023 Feb 12, 2024	BUY	$21.2 - $31.03 $512,594 - $750,274	24,179 Added 39.38%	85,583 $2.62 Million
Q3 2023 Nov 08, 2023	BUY	$26.2 - $36.08 $199,041 - $274,099	7,597 Added 14.12%	61,404 $1.65 Million
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $509,615 - $838,151	20,255 Added 60.37%	53,807 $1.92 Million
Q1 2023 May 11, 2023	BUY	$23.68 - $38.51 $47,502 - $77,251	2,006 Added 6.36%	33,552 $852,000
Q4 2022 Feb 08, 2023	BUY	$28.0 - $40.56 $303,688 - $439,913	10,846 Added 52.4%	31,546 $1.28 Million
Q3 2022 Nov 09, 2022	BUY	$29.63 - $48.31 $117,719 - $191,935	3,973 Added 23.75%	20,700 $683,000
Q2 2022 Aug 10, 2022	SELL	$27.79 - $50.61 $7,253 - $13,209	-261 Reduced 1.54%	16,727 $587,000
Q1 2022 May 12, 2022	BUY	$39.62 - $69.97 $31,180 - $55,066	787 Added 4.86%	16,988 $779,000
Q4 2021 Feb 10, 2022	BUY	$58.09 - $82.51 $437,824 - $621,877	7,537 Added 86.99%	16,201 $1.08 Million
Q3 2021 Nov 12, 2021	SELL	$58.38 - $84.96 $21,425 - $31,180	-367 Reduced 4.06%	8,664 $540,000
Q2 2021 Aug 06, 2021	SELL	$62.15 - $90.32 $60,907 - $88,513	-980 Reduced 9.79%	9,031 $747,000
Q1 2021 May 10, 2021	SELL	$61.35 - $90.47 $122,515 - $180,668	-1,997 Reduced 16.63%	10,011 $664,000
Q4 2020 Feb 10, 2021	BUY	$43.82 - $85.37 $186,322 - $362,993	4,252 Added 54.82%	12,008 $922,000
Q2 2020 Aug 10, 2020	BUY	$26.12 - $43.27 $15,619 - $25,875	598 Added 8.35%	7,756 $335,000
Q1 2020 May 21, 2020	SELL	$20.56 - $63.12 $67,498 - $207,222	-3,283 Reduced 31.44%	7,158 $206,000
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $31,657 - $82,136	1,125 Added 12.08%	10,441 $663,000
Q3 2019 Nov 12, 2019	SELL	$26.26 - $34.86 $2,626 - $3,486	-100 Reduced 1.06%	9,316 $264,000
Q2 2019 Aug 13, 2019	SELL	$17.43 - $28.82 $37,561 - $62,107	-2,155 Reduced 18.62%	9,416 $250,000
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $12,616 - $21,128	1,047 Added 9.95%	11,571 $211,000
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $27,107 - $49,722	-2,524 Reduced 19.34%	10,524 $131,000
Q3 2018 Nov 09, 2018	BUY	$14.0 - $20.3 $182,672 - $264,874	13,048 New	13,048 $251,000

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.07B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.

Account

High Tower Advisors, LLC Arrowhead Pharmaceuticals, Inc. Transaction History